GRAL
$47.37
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and...
Recent News
Assessing GRAIL (GRAL) Valuation After Recent Share Price Pullback And Ongoing Growth Challenges
Recent performance snapshot GRAIL (GRAL) has drawn attention after a sharp pullback, with the stock showing a one-month return of 57% and a three-month return of 52%, alongside a one-day move of 3%. For context, the company reports annual revenue of US$147.172m and a net income loss of US$408.351m, with revenue growth of 22% and net income growth of 5% on the latest annual figures provided. See our latest analysis for GRAIL. GRAIL’s share price has retreated sharply in recent weeks, with a 30...
Here’s What Analysts Are Saying About Grail Inc. (GRAL)
Grail Inc. (NASDAQ:GRAL) is one of the best small-cap stocks with huge growth potential. On February 20, Baird cut the price target on Grail Inc. (NASDAQ:GRAL) to $82 from $113 while maintaining an Outperform rating on the shares. The rating update came after the announcement that its NHS study missed its primary endpoint. The same […]
GRAIL (GRAL) Valuation Reassessed After NHS Galleri Trial Setback And Market Selloff
Why GRAIL stock is in focus after the NHS-Galleri setback GRAIL (GRAL) is back in the spotlight after its high profile NHS-Galleri trial failed to reach the primary goal of cutting advanced Stage III IV cancer diagnoses, a result that immediately hit sentiment around the Galleri blood test. See our latest analysis for GRAIL. The share price reaction has been severe, with a 1 day share price return of about a 51% decline and a 7 day share price return of about a 49% decline, taking the stock...
Grail Shares Crashes 50% After Major Cancer Screening Trial Fails Main Goal
Grail's three-year cancer screening trial misses its primary goal, sending shares down sharply
Stock Market Today: Nasdaq Charges Higher As Trump Announces Global Tariff; Nvidia Shares Rise (Live Coverage)
Stock Market Today: Stocks turned higher Friday after the Supreme Court ruled against President's Trump's global tariffs.